MobbleOpen in Mobble ⇢
Health · Aging & longevity · published 2026-09-15 · via MedPage Today

Liver Enzyme Ratio Tied to Faster Alzheimer's Decline; Lasker Awards Recognize Brain Research

Image via MedPage Today
Image via MedPage Today

A study of over 2,700 Alzheimer's Disease Neuroimaging Initiative participants found that higher baseline ratios of aspartate aminotransferase to alanine aminotransferase were associated with more rapid cognitive and cortical decline, particularly in APOE4 carriers. The findings were published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. Separately, the Lasker Awards honored sleep researchers for their work on the orexin system and actor Michael J. Fox for his Parkinson's foundation.

Expanded Detail

The study linking higher AST-to-ALT ratios with faster cognitive decline in Alzheimer’s patients highlights a potential blood-based marker for disease progression, especially among APOE4 carriers. This ratio, typically used to assess liver health, may reflect systemic metabolic changes that influence neurodegeneration. The finding adds to growing evidence that peripheral organ function interacts with brain aging, as separate imaging research also connected brain-gut communication to aging in younger adults.

The Lasker Awards this year spotlighted neuroscience breakthroughs, including the orexin system’s role in wakefulness and Michael J. Fox’s advocacy for Parkinson’s research. These honors underscore how basic science and patient-driven initiatives can reshape understanding of neurological conditions, from sleep disorders to movement diseases.

Context

This research could help clinicians identify Alzheimer’s patients at higher risk for rapid decline, enabling earlier or more aggressive interventions. It may also spur broader screening of liver enzymes in memory clinics, though the clinical utility remains uncertain. The Lasker recognition of brain science could raise public interest in neurological research funding, potentially accelerating translational work. However, the biomarker’s specificity and the ethical implications of asymptomatic Alzheimer’s blood tests, as noted in social media analyses, warrant careful consideration before widespread use.

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at MedPage Today →
Related stories
Trace Element Imbalances Tied to Dementia; Epilepsy Hinders Education; Navigating Brain Death Discussions · Aging & longevity
AI Speeds Up Rheumatology Diagnoses but Not Accuracy · Medical devices
Scientists Behind Orexin Discovery Honored with Lasker Prize · Drug development
BioVie Finishes Dosing in Long COVID Brain Fog Study, Data Due in September · Mental health
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Alzheimer's and Liver Enzymes; Pivotal Trial Hold; Lasker Awards Honor Brain Science.” Browse more stories.